Brazil researchers report disappointing 50.4% efficacy for CoronaVac vaccine

A coronavirus vaccine developed by China’s Sinovac showed “general efficacy” of 50.4% in a late-stage trial in Brazil, researchers said, barely enough for regulatory approval and far short of earlier indications. The latest results are a major disappointment for Brazil, as the Chinese vaccine is one of two that the federal government has lined up to begin immunisation during the second wave of the world’s second-deadliest COVID-19 outbreak.

Source: Reuters